KRAS and cancer: Compounds that covalently attach KRAS G12C [8], antagonists of RAS-membrane association and downstream effector signaling [9, 10] and strategies to target downstream signaling of KRAS by inhibition of PI3K/Akt or Raf/MEK/ERK have shown promise in preclinical models of RAS-induced cancer [11–14].